Quanterix Corp. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Quanterix Corporation (QTRX)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Quanterix develops and commercializes ultra-sensitive digital immunoassay platforms (Simoa technology) for life sciences research and diagnostics. The company sells instruments, consumables, and services to research labs, CROs, and biopharma companies. Key focus areas include neurology (Alzheimer's disease), oncology, and immunology.
Recent Developments:
- Acquisition of Emission, Inc. (Jan 2025): Acquired for $10M upfront plus potential milestones/earnouts to secure bead supply for next-gen instruments.
- Agreement to Acquire Akoya Biosciences (Jan 2025): Entered into a merger agreement to acquire Akoya (spatial biology) in an all-stock transaction, expected to close in Q2 2025.
- Product Launches: Launched LucentAD Complete (multi-marker Alzheimer's test) in Nov 2024 and received ISO 13485 certification in Jan 2025.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $137.4 million | $122.4 million | +12% |
| Gross Profit | $83.1 million | $74.2 million | +12% |
| Gross Margin | 60.5% | 60.7% | -0.2 pts |
| Net Loss | $(38.5) million | $(28.4) million | -36% (wider loss) |
| Operating Loss | $(52.6) million | $(46.0) million | -14% |
| Cash & Cash Equivalents | $56.7 million | $174.4 million | -67% |
| Marketable Securities | $232.4 million | $146.9 million | +58% |
| Total Liquidity | $289.1 million | $321.3 million | -10% |
| Operating Cash Flow | $(35.2) million | $(18.8) million | -87% (more negative) |
Note: The company has an accumulated deficit of $470.1 million as of Dec 31, 2024.
Material Changes vs. Prior Period
- Revenue Mix Shift: Service and other revenue grew 28% to $51.2 million, driven by Accelerator Laboratory volume. Product revenue remained flat ($79.7M) as a $5.3M increase in consumables was offset by a $5.3M decrease in instrument sales due to a constrained capital funding environment.
- Expense Growth: Selling, General, and Administrative (SG&A) expenses increased 14% to $101.6 million. This included a $3.7M increase in professional services related to remediating internal control weaknesses and acquisition due diligence.
- Restatement Impact: The company restated prior financial statements (2022-2023) due to material weaknesses in inventory valuation and revenue recognition controls. This resulted in a restated net loss for 2023 of $28.4 million (originally reported differently).
- Interest Income: Decreased 7% to $14.7 million due to lower interest rates and cash balances.
Guidance, Outlook, and Risks
Outlook & Guidance:
- Management expects to incur significant operating losses for at least the next 24 months as it invests in diagnostics, R&D (Simoa ONE instrument), and sales expansion.
- Instrument sales are expected to remain soft in 2025 due to capital constraints but should recover with the launch of Simoa ONE (expected end of 2025).
- Material revenue from new Lucent Diagnostics tests is not expected until 2025 or later.
- Internal Controls: The company identified two material weaknesses as of Dec 31, 2024: (1) Inventory valuation (including labor/overhead capitalization) and (2) Accelerator Laboratory revenue recognition. Remediation is ongoing through 2025.
- Merger Execution: The proposed Akoya merger is subject to stockholder approval, regulatory clearance, and other conditions. Failure to close could result in significant costs and distraction.
- Regulatory: FDA rules regarding Laboratory Developed Tests (LDTs) are evolving, potentially increasing regulatory burdens and costs for the company's diagnostic services.
- Liquidity: While current cash and marketable securities ($289.1M) are sufficient for 12+ months, future capital needs for the Akoya merger and operations may require additional financing.
Investor Verification Checklist
- Internal Control Remediation: Verify the timeline and progress of remediation for the inventory valuation and Accelerator Laboratory revenue material weaknesses.
- Merger Terms & Financing: Confirm the status of the Akoya merger approval process and the terms of the potential $30M bridge financing.
- Instrument Sales Pipeline: Assess the impact of the "constrained capital funding environment" on future instrument bookings and the readiness of the Simoa ONE launch.
- Restatement Implications: Review the impact of the 2022-2023 restatement on historical performance metrics and any ongoing legal or regulatory inquiries.
- Regulatory Path for LDTs: Monitor FDA enforcement discretion regarding LDTs and the company's strategy for transitioning tests to 510(k) or PMA clearance.